KAYO MOTOR
834058
Zhejiang Zoenn Design
300901
Zhejiang Meorient Commerce & Exhibition Inc.
300795
Fujian Zitian Media Technology
300280
Zhejiang Prulde Electric Appliance
301353
CN Stock MarketDetailed Quotes
002365 Qianjiang Yongan Pharmaceutical
- 8.87
- -0.16-1.77%
Market Closed Dec 13 15:00 CST
2.61BMarket Cap806.36P/E (TTM)
9.21High8.84Low65.76KlotVolume9.00Open9.03Pre Close59.09MTurnover2.70%Turnover RatioLossP/E (Static)294.68MShares10.0952wk High1.31P/B2.16BFloat Cap5.3552wk Low9.93Limit Up244.00MShs Float28.37Historical High8.13Limit Down4.10%Amplitude4.11Historical Low0.10Dividend TTM8.99Avg Price33.38KlotAsk1.13%Div YieldTTM100Lot Size31.13KlotBid
Qianjiang Yongan Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -22.93%618.72M | -26.39%425.82M | -36.80%196.64M | -33.48%972.89M | -28.52%802.82M | -30.05%578.44M | -24.51%311.17M | -6.58%1.46B | -0.20%1.12B | 16.12%826.91M |
| Operating revenue | -22.93%618.72M | -26.39%425.82M | -36.80%196.64M | -33.48%972.89M | -28.52%802.82M | -30.05%578.44M | -24.51%311.17M | -6.58%1.46B | -0.20%1.12B | 16.12%826.91M |
| Other operating revenue | ---- | -83.36%10.51M | ---- | -63.03%13.52M | ---- | 642.55%63.16M | ---- | 87.15%36.57M | ---- | 59.14%8.51M |
| Total operating cost | -23.81%583.88M | -26.97%387.99M | -43.44%175.01M | -24.94%965.62M | -20.53%766.38M | -24.20%531.25M | -13.39%309.42M | -11.05%1.29B | -6.65%964.33M | 6.21%700.81M |
| Operating cost | -15.34%471.87M | -20.01%313.33M | -36.42%140.27M | -26.47%721.21M | -29.32%557.37M | -34.23%391.69M | -26.25%220.6M | -18.73%980.79M | -3.36%788.58M | 13.90%595.58M |
| Operating tax surcharges | 5.02%7.62M | 2.59%4.87M | 59.43%3.09M | -26.17%10.09M | -37.52%7.26M | -34.95%4.74M | -47.11%1.94M | 17.97%13.66M | 26.04%11.62M | 28.08%7.29M |
| Operating expense | -80.47%11.89M | -82.68%7.88M | -90.27%3.93M | -56.48%54.5M | -29.83%60.88M | -5.53%45.49M | 96.96%40.4M | 58.99%125.23M | -21.39%86.75M | -29.99%48.16M |
| Administration expense | -38.50%68.78M | -34.21%47.99M | -35.97%22.49M | -1.40%145.22M | 63.74%111.83M | 67.68%72.95M | 53.04%35.12M | 64.70%147.27M | 19.60%68.3M | 22.54%43.5M |
| Financial expense | 3.42%-6.67M | -19.58%-7.63M | -439.86%-4.79M | 67.06%-6.9M | 71.00%-6.9M | 56.78%-6.38M | 34.35%1.41M | -414.62%-20.94M | -2,042.97%-23.8M | -1,115.89%-14.75M |
| -Interest expense (Financial expense) | 58.05%403.22K | 46.28%220.97K | 26.85%108.34K | -43.65%374.4K | -56.67%255.12K | -72.42%151.06K | -81.26%85.41K | -72.78%664.42K | -64.41%588.73K | -57.60%547.77K |
| -Interest Income (Financial expense) | -59.74%-1.34M | -37.56%-915.79K | -91.36%-660.74K | -455.14%-1.88M | -336.57%-837.34K | -365.41%-665.75K | -13.61%-345.29K | -118.84%-338.73K | 86.33%-191.8K | 87.40%-143.05K |
| Research and development | -15.49%30.38M | -5.26%21.55M | 0.69%10.02M | 2.60%41.5M | 9.29%35.95M | 8.14%22.74M | 0.16%9.95M | -23.74%40.45M | -16.11%32.89M | -17.60%21.03M |
| Credit Impairment Loss | -75.85%239.42K | -238.46%-1.36M | 32.27%-1.04M | -20.78%1.76M | -65.96%991.55K | 127.54%979.34K | -76.03%-1.53M | 121.30%2.22M | 142.58%2.91M | 47.10%-3.56M |
| Asset Impairment Loss | -105.97%-160.68K | ---- | ---- | -158.94%-96.57M | --2.69M | --3.53M | 208,102.17%5.24M | -615.64%-37.3M | ---- | ---- |
| Other net revenue | -11.21%34.31M | -11.52%23.27M | -7.82%12.51M | 93.12%-1.62M | 86.34%38.64M | 452.69%26.3M | 385.80%13.57M | -287.27%-23.59M | 146.69%20.74M | 12.35%4.76M |
| Fair value change income | -95.49%494.83K | -65.31%3.77M | -52.29%3.12M | 268.06%11.83M | 411.91%10.96M | 1,526.00%10.88M | 927.07%6.55M | -2,395.68%-7.04M | -53.79%-3.52M | -198.39%-762.96K |
| Invest income | 67.84%28.71M | 90.28%16.72M | 232.76%6.29M | 107.71%25.51M | 8.30%17.1M | 37.52%8.79M | -39.34%1.89M | -48.93%12.28M | -6.95%15.79M | -39.41%6.39M |
| -Including: Investment income associates | 165.10%3.98M | 271.10%3.27M | 187.11%1.1M | 124.08%2.66M | 325.32%1.5M | 128.88%881.26K | 9.55%-1.26M | -404.67%-11.04M | -145.83%-667K | -298.21%-3.05M |
| Asset deal income | -451.07%-724.23K | -6,765.23%-541.06K | ---50.26K | 139,914.19%45.02M | -148.65%-131.42K | -104.98%-7.88K | ---- | -112.65%-32.2K | --270.15K | --158.27K |
| Other revenue | -18.08%5.75M | 118.63%4.68M | 192.63%4.19M | 72.76%10.84M | 33.13%7.02M | -15.45%2.14M | 21.77%1.43M | 48.14%6.27M | 76.44%5.28M | 22.79%2.53M |
| Operating profit | -7.90%69.15M | -16.87%61.1M | 122.87%34.15M | -96.29%5.65M | -58.18%75.08M | -43.84%73.49M | -73.47%15.32M | 15.75%152.4M | 78.31%179.53M | 131.52%130.85M |
| Add:Non operating Income | 82.83%544.5K | -52.70%68.55K | -39.10%41.17K | -41.75%2.65M | -87.00%297.81K | -79.52%144.91K | -79.17%67.6K | 86.00%4.55M | 247.32%2.29M | 39.19%707.75K |
| Less:Non operating expense | -74.12%1.07M | -95.02%379.36K | 7.78%354.89K | -42.26%2.24M | 8.51%4.13M | 115.64%7.62M | -38.56%329.28K | -8.78%3.89M | 40.03%3.81M | 234.80%3.54M |
| Total profit | -3.68%68.62M | -7.92%60.79M | 124.66%33.83M | -96.05%6.05M | -59.98%71.25M | -48.44%66.01M | -73.83%15.06M | 17.87%153.06M | 80.49%178.01M | 128.73%128.03M |
| Less:Income tax cost | -67.42%9.82M | 7.55%9.67M | 292.42%5.36M | 69.45%34.47M | 29.89%30.16M | -45.65%9M | -81.70%1.37M | 88.25%20.34M | 159.53%23.22M | 260.42%16.55M |
| Net profit | 43.11%58.8M | -10.36%51.11M | 107.94%28.48M | -121.41%-28.41M | -73.46%41.09M | -48.85%57.02M | -72.66%13.69M | 11.49%132.72M | 72.61%154.79M | 116.96%111.47M |
| Net profit from continuing operation | 43.11%58.8M | -17.85%46.84M | 107.94%28.48M | -147.57%-52.12M | -73.46%41.09M | -48.85%57.02M | -72.66%13.69M | -7.95%109.58M | 72.61%154.79M | 116.96%111.47M |
| Net income from discontinuing operating | ---- | --4.27M | ---- | 2.47%23.71M | ---- | ---- | ---- | --23.14M | ---- | ---- |
| Less:Minority Profit | 42.80%-3.06M | -253.70%-1.37M | 84.17%-203.94K | -111.07%-16.1M | 22.18%-5.34M | 117.44%892.69K | -154.55%-1.29M | -199.99%-7.63M | -194.43%-6.86M | -223.20%-5.12M |
| Net profit of parent company owners | 33.23%61.86M | -6.49%52.49M | 91.42%28.68M | -108.77%-12.31M | -71.28%46.43M | -51.86%56.13M | -70.38%14.98M | 25.97%140.35M | 96.16%161.65M | 146.88%116.59M |
| Earning per share | ||||||||||
| Basic earning per share | 33.57%0.2105 | -6.51%0.1781 | 91.54%0.0973 | -108.78%-0.0418 | -71.35%0.1576 | -52.38%0.1905 | -69.19%0.0508 | 26.65%0.4762 | 89.66%0.55 | 150.00%0.4 |
| Diluted earning per share | 33.57%0.2105 | -6.51%0.1781 | 91.54%0.0973 | -108.78%-0.0418 | -71.35%0.1576 | -52.38%0.1905 | -70.45%0.0508 | 25.81%0.4763 | 89.66%0.55 | 150.00%0.4 |
| Other composite income | -166.00%-2.05M | -157.06%-1.94M | -118.91%-1.96M | -82.34%894.75K | -47.39%3.11M | 28.90%3.39M | -406.76%-895.81K | 725.75%5.07M | 5,103.33%5.92M | 1,049.41%2.63M |
| Other composite income of parent company owners | -166.00%-2.05M | -157.06%-1.94M | -118.91%-1.96M | -82.34%894.75K | -47.39%3.11M | 28.90%3.39M | -406.76%-895.81K | 725.75%5.07M | 5,103.33%5.92M | 1,049.41%2.63M |
| Total composite income | 28.38%56.74M | -18.59%49.18M | 107.17%26.52M | -119.97%-27.52M | -72.50%44.2M | -47.06%60.41M | -74.35%12.8M | 16.54%137.79M | 79.44%160.7M | 123.28%114.1M |
| Total composite income of parent company owners | 20.71%59.8M | -15.07%50.55M | 89.67%26.72M | -107.85%-11.42M | -70.44%49.54M | -50.08%59.52M | -72.06%14.09M | 31.47%145.42M | 103.63%167.57M | 153.95%119.22M |
| Total composite income of minority owners | 42.80%-3.06M | -253.70%-1.37M | 84.17%-203.94K | -111.07%-16.1M | 22.18%-5.34M | 117.44%892.69K | -154.55%-1.29M | -199.99%-7.63M | -194.43%-6.86M | -223.20%-5.12M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
